Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 48: 291-300, 2002;
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Supplemental Data
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Web of Science (2)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Schiele, F.
Right arrow Articles by Herbeth, B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Schiele, F.
Right arrow Articles by Herbeth, B.
Related Collections
Right arrow Laboratory Management
Right arrow Lipids, Lipoproteins, and Cardiovascular Risk Factors
(Clinical Chemistry. 2002;48:291-300.)
© 2002 American Association for Clinical Chemistry, Inc.

Apolipoprotein E in Apolipoprotein B (apo B)- and Non-apo B-containing Lipoproteins in 3523 Participants in the Stanislas Cohort: Biological Variation and Genotype-specific Reference Limits

Françoise Schiele1, Monique Vincent-Viry1, Marjorie Starck1, Brigitte Beaud1, Geneviève Hennache2, Gérard Siest1, Sophie Visvikis1 and Bernard Herbeth1a

1 Centre de Médecine Préventive, INSERM U525, 2 Rue du Doyen Jacques Parisot, F54500 Vandoeuvre-lès-Nancy, France.

2 Sebia, 23 Rue Maximilien Robespierre, F92130 Issy-les-Moulineaux, France.

aAuthor for correspondence. Fax 33-3-83-44-87-21; e-mail Bernard.Herbeth{at}cmp.u-nancy.fr.

Background: Apolipoprotein (apo) E is a component of two major classes of plasma lipoproteins, apo B- (apo E-LpB) and non-apo B-containing (apo E-Lp-non-B) lipoproteins. The factors that affect total apo E in particles [lipoprotein E (LpE), apo E-Lp-non-B, and apo E-LpB], are incompletely characterized.

Methods: We studied the determinants of these lipoparticles in a sample population of presumably healthy individuals: 1784 children (age range, 8–18 years) and 1739 adults (age range, 19–50 years). Serum concentrations of LpE and apo E-Lp-non-B were measured by electroimmunoassays, and the concentration of apo E-LpB was calculated by a difference method.

Results: Serum LpE and apo E-Lp-non-B were higher in females than in males. Their concentrations decreased with age until 20–25 years and then increased in men but not in women. apo E-LpB concentrations increased up to 20–25 years and were similar in both sexes. Thereafter, adult men had higher values than women. Individuals carrying the {epsilon}2 allele had higher mean apo E-Lp-non-B concentrations and lower apo E-LpB concentrations than did individuals carrying the {epsilon}3 allele. Individuals with the {epsilon}4 allele showed an inverse profile compared with those with the {epsilon}2 allele. Age, gender, the common apo E polymorphism, puberty, serum lipid concentrations, and alcohol consumption were significantly associated with total LpE, apo E-Lp-non-B, and apo E-LpB concentrations. Reference limits were established according to age, gender, and the common apo E polymorphism.

Conclusions: Because measurements of LpE, apo E-Lp-non-B, and apo E-LpB concentrations may improve cardiovascular risk assessment, the proposed reference limits will aid interpretation of the results in clinical or therapeutic trials.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2002 by the American Association for Clinical Chemistry.